Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

626
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
626
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

632
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
632
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

753
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

602
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
602

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in Pulmonary Artery Pressure Following Initiation of Guideline-Directed Medical Therapies in Patients With Heart Failure: Insights From GUIDE-HF.

Circulation. Heart failure·2026
Same author

Admission Kidney Tubule Biomarkers Do Not Predict Acute Kidney Injury or In-Hospital Adverse Events in Acute Heart Failure.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association·2026
Same author

Urine Tubular Biomarkers Are Associated With Natriuresis in Patients With Acute Heart Failure.

Journal of the American Heart Association·2025
Same author

Kidney Tubular Biomarkers Predict Risk of Death and Heart Failure Readmission in Acute Heart Failure.

Journal of the American Heart Association·2025
Same author

Racial differences in diuretic therapy, B-type natriuretic peptide values, and prognosis in acute heart failure.

Journal of cardiology·2025
Same author

Absence of Kidney Tubular Injury in Patients With Acute Heart Failure With Acute Kidney Injury.

Circulation. Heart failure·2024

Related Experiment Video

Updated: Apr 30, 2026

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
09:29

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

1.4K

Using galectin-3 to reduce heart failure rehospitalization.

Yang Xue1, Alan Maisel, W Frank Peacock

  • 1Division of Cardiology, University of California San Diego, La Jolla, CA, USA.

Future Cardiology
|April 26, 2014
PubMed
Summary

Galectin-3, a biomarker for inflammation and fibrosis, is linked to heart failure readmissions and mortality. Measuring galectin-3 may help personalize heart failure management and improve patient outcomes.

More Related Videos

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.8K
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

11.4K

Related Experiment Videos

Last Updated: Apr 30, 2026

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice
09:29

An Experimental Model of Myocardial Infarction for Studying Cardiac Repair and Remodeling in Knockout Mice

Published on: July 14, 2023

1.4K
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

24.8K
Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

11.4K

Area of Science:

  • Cardiology
  • Biomarker Research
  • Heart Failure Management

Background:

  • Reducing short-term heart failure readmissions is a growing clinical concern.
  • Galectin-3 is a biomarker associated with myocardial inflammation, fibrosis, and adverse cardiac remodeling.
  • Elevated galectin-3 levels correlate with increased mortality and heart failure readmission risk.

Purpose of the Study:

  • To explore the role of galectin-3 as a biomarker in heart failure management.
  • To assess the predictive value of galectin-3 for adverse cardiovascular events.
  • To evaluate the potential of galectin-3 in developing individualized risk profiles for heart failure patients.

Main Methods:

  • Analysis of galectin-3 levels in heart failure patients.
  • Correlation of galectin-3 levels with clinical outcomes, including mortality and readmissions.
  • Comparison of galectin-3's predictive value against established biomarkers like natriuretic peptides.

Main Results:

  • Galectin-3 is a biomarker of inflammation and fibrosis in heart failure.
  • Higher galectin-3 levels are associated with increased risk of mortality and heart failure readmission.
  • Galectin-3 provides incremental predictive value beyond natriuretic peptides for adverse events.

Conclusions:

  • Galectin-3 shows potential as a key biomarker in future heart failure management strategies.
  • Individualized risk assessment using galectin-3 can optimize resource allocation and treatment.
  • Further research is needed to fully define galectin-3's role in clinical algorithms.